17th ANNUAL MIAMI CANCER MEETING (MCM)

Immunotherapy and Targeted Therapy in 2020: Moving Forward with Personalized Cancer Therapy

May 1-3, 2020
Trump National Doral Miami
Miami, Florida

PROGRAM DIRECTORS:

Luis E. Raez, MD, FACP, FCCP
President, Florida Society of Clinical Oncology (FLASCO)
Chief Scientific Officer & Medical Director
Memorial Cancer Institute
Clinical Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Miami, FL

Edgardo S. Santos Castillero, MD, FACP
Florida Precision Oncology (FPO)
Medical Oncology
Clinical Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Aventura, FL

In Collaboration with:
Florida Society of Clinical Oncology
Oncology Latin
American Association

Accredited by:
THE MEDICAL EDUCATOR CONSORTIUM
EDUCATIONAL COMMITTEE

Sanjiv S. Agarwala, MD  
Professor and Chief  
Hematology and Oncology  
St Luke's Cancer Center  
Temple University School of Medicine  
Bethlehem, PA  

Amanda Brahim, PharmD, BCOP, BCPS, BCACP  
Pharmacy Clinical Manager, Hematology-Oncology-BMT  
Residency Program Director, PGY2 Oncology Pharmacy  
Memorial Cancer Institute  
Pembroke Pines, FL  

Mariana Chavez-McGregor, MD, MSc  
Associate Professor, Tenured  
Department of Health Services Research  
Division of OVP, Cancer Prevention and Populuation Sciences  
The University of Texas MD Anderson Cancer Center  
Houston, TX  

Gerardo Colón-Otero, MD  
Professor of Medicine  
Mayo Clinic College of Medicine  
Dean, Mayo Clinic School of Medicine Florida Campus  
Division of Hematology-Oncology  
Mayo Clinic Cancer Center  
NCI Designated Comprehensive Cancer Center  
Jacksonville, FL  

Dina B. Dumercy McHenry, PharmD, BCOP, BCPS  
Director of Pharmacy Services  
Miami Cancer Institute, Baptist Health South Florida  
Miami, FL  

Luis E. Fayad, MD  
Professor in Medicine  
Department of Lymphoma and Myeloma  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX  

Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE  
Assistant Vice President  
System Oncology Pharmacy Services  
Non-Oncology Infusion Center Pharmacy Services  
Corporate Pharmacy Clinical Enterprise  
Miami Cancer Institute, Baptist Health South Florida  
Member, Memorial Sloan Kettering Cancer Alliance  
Miami, FL  

DISTINGUISHED FACULTY

Sergio Giralt, MD  
Melvin Berlin Family Chair in Myeloma Research  
Professor of Medicine Weill Cornell Medical College  
Chief Attending, Adult BMT Service  
Memorial Sloan Kettering Cancer Center  
New York, NY  

Jhanelle E. Gray, MD  
Co-Leader, Chemical Biology and Molecular Medicine  
Director, Thoracic Clinical Research  
Effective January 1, 2020 - Senior  
Moffit Medical Group  
Department of Thoracic Oncology &  
Department of Tumor Biology  
Associate Professor Oncologic Sciences  
University of South Florida  
Morsani College of Medicine  
Tampa, FL  

D. Constanza Guaqueta, MD  
Breast Medical Oncologist  
Memorial Cancer Institute  
Hollywood, FL  

Robert Haddad, MD  
Chief, Division of Head and Neck Oncology  
Institute Physician  
Dana Farber Cancer Institute  
Professor of Medicine  
Harvard Medical School  
Boston, MA  

Michael Hurwitz, MD, PhD  
Assistant Professor of Medicine  
Section of Medical Oncology  
Yale Comprehensive Cancer Center  
New Haven, CT  

Atif M. Hussein, MD  
Chief of Oncology/Hematology Services  
Memorial Cancer Institute  
Hollywood, FL  

Christine L. Ibarra, PharmD, BCPS  
Clinical Pharmacy Specialist, Thoracic Clinic  
Miami Cancer Institute, Baptist Health South Florida  
Miami, FL
Mohamed A. Kharfan-Dabaja, MD, MBA, FACP
Professor of Medicine
Vice-chair, Hematology
Director, Blood and Marrow Transplantation and Cellular Therapies
Director, Inpatient Hematology Service
Mayo Clinic Florida
Jacksonville, FL

Richard D. Kim, MD
Service Chief, GI Oncology
Department of Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
University of South Florida
Tampa, FL

Ticiana A. Leal, MD
Assistant Professor of Medicine
Thoracic Oncology Program Director
Division of Hematology, Medical Oncology and Palliative Care
University of Wisconsin School of Medicine and Public Health
Madison, WI

Ashwin Mehta, MD, MPH
Medical Director of Integrative Medicine
Medical Director of Physician Wellness
Memorial Healthcare System
Hollywood, FL

Shanu Modi, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Alberto J. Montero, MD, MBA, CPHQ
Staff Physician, Cleveland Clinic
Medical Breast Oncology
Taussig Cancer Institute
Cleveland, OH

Daniel Petrylak, MD
Director, Genitourinary Oncology Research Program
Co-Director, Signal Transduction Program
Yale Comprehensive Cancer Center
New Haven, CT

Javier Pinilla-Ibarz, MD, PhD
Senior Member and Head, Lymphoma Service
Moffitt Cancer Center
Tampa, FL

Luis E. Raez, MD, FACP, FCCP
President, Florida Society of Clinical Oncology (FLASCO)
Chief Scientific Officer & Medical Director
Memorial Cancer Institute
Clinical Professor of Medicine
Herbert Wertheim College of Medicine
Florida International University
Miami, FL

Caio Max S. Rocha-Lima, MD, MS
M. Robert Cooper, Professor in Medical Oncology
Co-Leader GI Oncology and Co-Leader Phase I Program
Division of Hematology and Oncology
Wake Forest School of Medicine
Winston-Salem, NC

Rosanna Rodriguez, PA-C, MPH
Inpatient Consult Service
Division of Solid Tumor and Benign Hematology
Memorial Cancer Institute West
Pembroke Pines, FL

Christian Rolfo, MD, PhD, MBA, Dr.h.c.
Professor of Medicine
Director of Thoracic Medical Oncology Program
Director of Early Clinical Trials
Experimental Therapeutics Research Program
University of Maryland School of Medicine
Baltimore, MD

Maray Salina, MSN, APRN, FNP-BC
Director of Oncology Support Services
Memorial Healthcare Services
Hollywood, FL

Jose D. Sandoval-Sus, MD, FACP
Assistant Member
Department of Malignant Hematology & Cellular Therapy
Moffitt Cancer Center
Memorial Health Care System
Hollywood, FL

Edgardo S. Santos Castillero, MD, FACP
Florida Precision Oncology (FPO)
Medical Oncology
Clinical Associate Professor
Charles E. Schmidt College of Medicine
Florida Atlantic University
Aventura, FL

Janakiraman Subramanian, MD, MPH
Associate Professor of Medicine
Director of Thoracic Oncology and Center for Precision Oncology
Saint Lukes Cancer Institute
University of Missouri Kansas City
Kansas City, MO

Michel Velez, MD
Director of Breast & GI Malignancies
Medical Oncology Division
Michael and Dianne Bienes Cancer Center
Holy Cross Hospital
Clinical Coordinator, University of Miami Residency Program
Hematology Oncology Division, HCH
Assistant Professor, Clinical Biomedicine
Florida International University
Florida Atlantic University
Fort Lauderdale, FL
CONFERENCE DESCRIPTION
This 3-day conference is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician assistants (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners (internal medicine and family medicine) will have the benefit of review standard of care and new developments in cancer management. Residents in training and fellows from these specialties are encouraged to attend.

Topics in solid tumors and hematological malignancies will be reviewed and will include topics in breast cancer, lung cancer, gastrointestinal (GI) malignancies, gynecologic malignancies, genitourinary (GU) cancers, head and neck cancers, melanoma, and hematological malignancies such as multiple myeloma, CLL and non-Hodgkin’s lymphoma. There will also be a special session devoted to the area of palliative care, survivorship in oncology, targeted therapy and immunotherapy side effects management.

The areas of focus for this conference will include the current standards of care in the treatment of all aforementioned malignancies and new developments in these areas of cancer care. There will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles. There will be reviews of new chemotherapeutic, antiangiogenic and immunotherapeutic agents.

Presentations from the latest national (AACR, ASCO, SABC, and ASH) and international forums (ESMO and WCLC) meetings will be discussed and guidelines of cancer care using a team approach will be emphasized. The participants in the conference will have the opportunity not only to learn, review, and understand the state-of-the-art management in cancer care using a team approach but also engage in personal interaction with our panel of experts in these subjects during the question and answer sessions.

CONFERENCE OBJECTIVES
Upon completion of this conference attendees will be able to:

1. Recognize the latest advances in chemotherapy, targeted therapy and immunotherapy options available for lung cancer, breast cancer, GI malignancies, GU malignancies, melanoma, head and neck cancer as well as hematological malignancies including multiple myeloma, NHL, AML, and CLL.

2. Evaluate the current standards of care in the treatment of a variety of solid and hematologic malignancies.

3. Discuss risks and benefits when combined modality of treatment (that includes radiation therapy and surgery) is being delivered to patients who have localized malignant processes (i.e., NSCLC, head and neck, prostate cancer, and others).

4. Formulate an individualized plan of care using a team approach to manage symptoms induced by chemotherapy, immunotherapy or targeted therapy such as auto immune complications, hematologic and metabolic toxicities.

ACCREDITATION AND CREDIT STATEMENTS
In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
The Medical Educator Consortium designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
“Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.”

Nursing
The Medical Educator Consortium designates this activity for 15.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

Pharmacist
This Application-based activity has been approved for 15.5 contact hours (1.25 CEUs) by the The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-20-014-L01-P. This learning activity is Application-based. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Assistant
The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 15.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Policy
The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
**17TH ANNUAL MIAMI CANCER MEETING (MCM):**

*Immunotherapy and Targeted Therapy in 2020: Moving Forward with Personalized Cancer Therapy*

**May 1-3, 2020**

*Trump National Doral Miami*

*Doral, Florida*

**PROGRAM AGENDA**

**Day 1 | Friday, May 1, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 pm – 7:30 pm</td>
<td>Registration</td>
</tr>
<tr>
<td>12:30 pm – 2:30 pm</td>
<td>Lunch &amp; Learn Symposia <em>(Non-CME/CE)</em></td>
</tr>
<tr>
<td>2:30 pm – 3:00 pm</td>
<td>Visit Exhibits</td>
</tr>
</tbody>
</table>
| 3:00 pm – 3:10 pm | **WELCOME AND INTRODUCTION**  
Luis E. Raez, MD, FACP, FCCP & Edgardo S. Santos Castillero, MD, FACP  
Program Co-Directors |
| 3:10 pm – 6:00 pm | **Toxicity Profiles, Supportive Care and Challenges in Cancer Therapy Session**  
Chairs: Dina B. Dumercy, PharmD BCOP, BCPS & Jorge J. Garcia, PharmD, MS, MBA, FACHE |
| 3:10 pm – 3:40 pm | New Agents and New Toxicities in Malignant Hematology:  
BCL2 Inhibitors and FLT3 Inhibitors  
Amanda Brahim, PharmD, BCOP, BCPS, BCACP |
| 3:40 pm – 4:10 pm | Management of Immunotherapy Related Adverse Events in Solid Tumors  
Christina L. Ibarra, PharmD, BCPS |
| 4:10 pm – 4:40 pm | Integrative Medicine in Cancer Care: What the patients should know  
Ashwin Mehta, MD, MPH |
| 4:40 pm – 5:10 pm | Biosimilars, Beyond the Scientific Review  
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE |
| 5:10 pm – 5:40 pm | Cancer Survivorship: What are the Current Standards of Care in Solid Tumors  
Maray Salina, MSN, APRN, FNP-MC |
| 5:40 pm – 6:00 pm | Round Table Discussion | Q & A Session  
Panel: Brahim, Garcia, Ibarra, Mehta, Salina |
| 6:00 pm – 6:20 pm | Refreshment Break | Visit Exhibits |
| 6:20 pm – 7:30 pm | **Head & Neck Cancers, Brain Tumors and Sarcoma Session**  
Chair: Rossana Rodriguez, PA-C, MPH |
| 6:20 pm – 6:50 pm | New Approaches for Squamous Cell Carcinoma of Head and Neck and Thyroid Tumors  
Robert Haddad, MD |
| 6:50 pm – 7:20 pm | Systemic and Combined Therapy for Brain Malignancies and Soft Tissue Sarcomas  
Atif M. Hussein, MD |
| 7:20 pm – 7:30 pm | Round Table Discussion | Q & A Session  
Panel: Haddad, Hussein |
| 7:30 pm – 9:00 pm | Dinner & Learn Symposium *(Non-CME/CE)*  
(subject to availability) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am –</td>
<td>Registration</td>
</tr>
<tr>
<td>7:45 am – 9:00 am</td>
<td>Immunotherapy Session</td>
</tr>
<tr>
<td>7:45 am – 8:15 am</td>
<td>Immunotherapy in Kidney &amp; Bladder Tumors</td>
</tr>
<tr>
<td>8:15 am – 8:45 am</td>
<td>Immunotherapy for Melanoma</td>
</tr>
<tr>
<td>8:45 am – 9:00 am</td>
<td>Round Table Discussion</td>
</tr>
<tr>
<td>9:00 am – 10:00 am</td>
<td>Breakfast &amp; Learn Symposium (Non-CME/CE)</td>
</tr>
<tr>
<td>10:00 am – 10:10 am</td>
<td>Coffee</td>
</tr>
<tr>
<td>10:10 am – 12:20 pm</td>
<td>Lung Cancer Session</td>
</tr>
<tr>
<td>10:10 am – 10:40 am</td>
<td>EGFR/ALK and ROS-1 Lung Cancer Management</td>
</tr>
<tr>
<td>10:40 am – 11:10 am</td>
<td>Uncommon Mutations: RET, MET, NTRK, &amp; BRAF</td>
</tr>
<tr>
<td>11:10 am – 11:40 am</td>
<td>Lung Cancer Neoadjuvant and Adjuvant Immunotherapy</td>
</tr>
<tr>
<td>11:40 am – 12:10 pm</td>
<td>How to Choose Front Line Therapy for Metastatic NSCLC</td>
</tr>
<tr>
<td>12:10 pm – 12:20 pm</td>
<td>Round Table Discussion</td>
</tr>
<tr>
<td>12:20 pm – 1:20 pm</td>
<td>Lunch &amp; Learn Symposium (Non-CME/CE)</td>
</tr>
<tr>
<td>1:20 pm – 1:40 pm</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>1:40 pm – 2:50 pm</td>
<td>Genitourinary and Gynecologic Malignancies Session</td>
</tr>
<tr>
<td>1:40 pm – 2:10 pm</td>
<td>Gynecologic Malignancies</td>
</tr>
<tr>
<td>2:10 pm – 2:40 pm</td>
<td>Prostate and Bladder Cancer</td>
</tr>
<tr>
<td>2:40 pm – 2:50 pm</td>
<td>Round Table Discussion</td>
</tr>
</tbody>
</table>
### 17th Annual Miami Cancer Meeting (MCM):

**Immunotherapy and Targeted Therapy in 2020:**
**Moving Forward with Personalized Cancer Therapy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 2:50 pm – 3:50 pm | International Society of Liquid Biopsies (ISLB) and MCM Symposia: Liquid Biopsies and New Biomarkers for Cancer Diagnosis and Therapy  
*Chair: Luis E. Raez, MD, FACP, FCCP* |                                    |
| 2:50 pm – 3:10 pm  | Liquid Biopsies in Lung Cancer  
*Christian Rolfo, MD, PhD, MBA, Dr.h.c.* |                                    |
| 3:10 pm – 3:40 pm  | Predictive and Prognostic: Value of TMB, MSI and PD-L1 in Liquid and Solid Tumor Specimens  
*Ticiana A. Leal, MD* |                                    |
| 3:40 pm – 3:50 pm  | Round Table Discussion | Q & A Session  
*Panel: Leal, Rolfo* |                                    |
| 3:50 pm – 4:10 pm  | **Refreshment Break | Visit Exhibits** |                                    |
| 4:10 pm – 5:40 pm  | **Gastrointestinal Malignancies Session**  
*Chair: Caio Rocha-Lima, MD* |                                    |
| 4:10 pm – 4:40 pm  | Gastric and Esophageal Cancer Updates  
*Caio Rocha-Lima, MD* |                                    |
| 4:40 pm – 5:10 pm  | Metastatic Colorectal Cancer Therapy  
*Richard D. Kim, MD* |                                    |
| 5:10 pm – 5:40 pm  | Round Table Discussion | Q & A Session  
*Panel: Kim, Rocha-Lima* |                                    |
# 17th Annual Miami Cancer Meeting (MCM):
## Immunotherapy and Targeted Therapy in 2020: Moving Forward with Personalized Cancer Therapy

**Day 3 | Sunday, May 3, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am – 8:00 am</td>
<td>Registration</td>
</tr>
<tr>
<td>8:00 am – 8:20 am</td>
<td>Hematology Malignancies Session Chair: Jose Sandoval-Sus, MD, FACP</td>
</tr>
<tr>
<td>8:20 am – 11:10 am</td>
<td>Chronic Lymphocytic and Myeloid Leukemias Javier Pinilla-Ibarz, MD, PhD</td>
</tr>
<tr>
<td>8:20 am – 9:00 am</td>
<td>Hodgkin’s and Non-Hodgkin’s Lymphomas Luis E. Fayad, MD</td>
</tr>
<tr>
<td>9:00 am – 10:00 am</td>
<td>Breakfast &amp; Learn Symposium (Non-CME/CE)</td>
</tr>
<tr>
<td>10:00 am – 10:40 am</td>
<td>Coffee</td>
</tr>
<tr>
<td>10:40 am – 11:10 am</td>
<td>Hematology Malignancies Case Presentations and Round Table Discussion Presenter: Jose Sandoval-Sus, MD, FACP Panel: Fayad, Giralt, Kharfan-Dabaja, Pinilla-Ibarz</td>
</tr>
<tr>
<td>11:10 am – 1:00 pm</td>
<td>Breast Cancer Session Chair: D. Constanza Guaqueta, MD</td>
</tr>
<tr>
<td>11:10 am – 11:30 am</td>
<td>Breast Cancer Immunotherapy Mariana Chavez-McGregor, MD, MSc</td>
</tr>
<tr>
<td>11:30 am – 11:50 am</td>
<td>HER2-Driven Breast Cancer: Current Status and Next Generation Therapeutics Shanu Modi, MD</td>
</tr>
<tr>
<td>11:50 am – 12:10 pm</td>
<td>Hormonal Therapy in Breast Cancer Alberto Montero, MD, MBA, CPHQ</td>
</tr>
<tr>
<td>12:10 pm – 12:30 pm</td>
<td>Parp Inhibitors and Chemotherapy for Breast Cancer D. Constanza Guaqueta, MD</td>
</tr>
<tr>
<td>12:30 pm – 1:00 pm</td>
<td>Breast Cancer Case Presentations and Round Table Discussion Presenter: Michel Velez, MD Panel: Chavez-McGregor, Guaqueta, Modi, Montero, Velez</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Closing Remarks and Meeting Adjourns</td>
</tr>
</tbody>
</table>
This iconic Miami hotel pairs legendary, championship golf courses with breathtaking views and elegant surroundings in a world-class destination infused with the standard of excellence, conveniently located 8 miles from Miami International Airport.

The prestigious 800-acre resort boasts four championship golf courses in Miami, among them the legendary Blue Monster, various recreational amenities, including brand new Har-Tru tennis courts, and a lively clubhouse, the hub of the resort. The Royal Palm Pool, with 18 private cabanas and a 125-foot slide, is the perfect setting for Miami weekend getaways, soaking in some sun, or poolside fun with your family.

The hotel is offering special rates during this conference of $239 run of house plus a $10 hotel service fee and tax. This rate is European plan (no meals). The cutoff date to make reservations is February 19, 2020, after this date reservations are subject to hotel availability.

Make your reservation today by calling 1-800-713-6725 or 305-592-2000 and identify yourself as attending the “Miami Cancer Meeting.”
REGISTRATION FORM

17th Annual Miami Cancer Meeting (MCM)

Immunotherapy and Targeted Therapy in 2020: 
Moving Forward with Personalized Cancer Therapy

Register online at www.meccinc.com or fax to 305/675-2718 (PRINT CLEARLY)

Name_____________________________________ Degree ______________________
Address ____________________________________________________________________
City ______________________________________________________________________
State __________________________________ Zip ____________________________
Telephone (___)________________________________ Fax (___)_______________
Email address _____________________________________________________________ Specialty __________________

License (Letters & Numbers): _____________________ State License Issued: _____________

Pharmacists

NABP ePID: ______________________________ Date of Birth (month/day) _______

Type of Practice:  □ Private   □ Academic   □ Other
                  □ Hospital   □ Resident/Fellow

REGISTRATION FEE:

Early bird pricing - BEFORE March 2, 2020
$225 Physicians
$95 Residents/Fellows, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists & Other Health Professionals
$300 Industry Professionals - Confirmed Exhibiting Company
$1000 Industry Professionals - Not associated with an Exhibiting Company

AFTER March 2, 2020
$275 Physicians
$115 Residents/Fellows, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists & Other Health Professionals
$350 Industry Professionals - Confirmed Exhibiting Company
$1000 Industry Professionals - Not associated with an Exhibiting Company

I authorize MECC to charge my credit card i/a/o $_________ for registration of this conference using the following credit card.

Name on Card ___________________________________ Exp. Date ___________
Card number ___________________________________________ CVV ___________
Authorized signer _____________________________________________

If you require special assistance or have specific dietary requirements, please contact MECC, Inc. by no later than March 2, 2020 via email at info@meccinc.com
17th Annual Miami Cancer Meeting (MCM):

Immunotherapy and Targeted Therapy in 2020: Moving Forward with Personalized Cancer Therapy

May 1-3, 2020

Trump National Doral Miami

Miami, Florida